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Background: To evaluate the feasibility and early side effects of a short course hypo-fractionated SBRT programme
with Volumetric Modulated Arc Therapy (VMAT) and Flattening Filter Free (FFF) beams.
Methods: A prospective phase I-II study, started on February 2012. Inclusion criteria were: age ≤ 80 years, WHO-PS
≤ 2, PSA ≤ 20 ng/ml, histologically proven prostate adenocarcinoma, T1-T2 stage, no distant metastases, no previous
surgery other than TURP, no malignant tumours in the previous 5 years, IPSS 0–7. The schedule was 35 Gy in
5 alternative days. SBRT was delivered with RapidArc VMAT, with 10MV FFF photons. Toxicity assessment was
performed according to CTCAE v4.0 scale. EPIC questionnaires assessed Quality-of-Life. Neo-adjuvant/concomitant
hormonal-therapy was prescribed according to risk classification. SpaceOAR™ gel was optionally implanted to
increase the separation space between the prostate and the rectal wall.
Results: Median follow-up was 11 months (range: 5–16); 40 patients were recruited in the protocol and treated.
According to NCCN criteria, 26/40 patients were low-risk and 14/40 were intermediate risk. Median age was
70 years (56–80), median initial PSA was 6.25 ng/ml (0.50-13.43 ng/ml). Median Gleason score was 6 (6–7). All
patients completed the treatment as programmed (median 11.8 days (9–22). Acute Toxicities were as follow:
Rectum G0: 30/40 cases (75%); G1: 6/40 (15%); G2: 4/40 (10%). Genito-urinary: G0: 16/40 (40%); G1: 8/40 (20%);
G2: 16/34 (40%). In two G2 urinary retention cases, intermittent catheter was needed. No acute G3 or greater
toxicity was found. Median treatment time was 126 sec (120–136). SpaceOAR™ was implanted in 8 patients. PSA
reduction from the pre-treatment value of the marker was documented in all patients.
Conclusions: Early findings suggest that SBRT with RapidArc and FFF beams for prostate cancer in 5 fractions is
feasible and tolerated in acute setting. Longer follow-up is needed for assessment of late toxicity and outcome.
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In organ-confined prostate cancer, radical prostatectomy
is the most common therapeutic procedure for disease
eradication. Various radiation therapy (RT) techniques
have been considered an effective non-invasive treat-
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reproduction in any medium, provided the orunfit for surgery. Historically, brachytherapy has played
a significant role in the radical treatment of prostate
cancer, particularly in the subgroup of low-risk patients
with a small prostatic gland and good urinary flow.
Brachytherapy irradiates the prostatic gland through an
intense intra-prostatic dose while minimizing irradiation
of organs at risk, and is especially good at sparing the
anterior rectal wall, and the urethra and bladder neck.
Recent innovations in external beam radiotherapy
(EBRT) which combine image-guided radiotherapy
(IGRT) and intensity-modulated radiotherapy (IMRT),Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Patient characteristics
N. of patients 40
Median Age [year] 70 [56, 80]
Median Initial PSA [ng/mL] 6.25 [0.50, 13.43]
Median Gleason Score 6 [6,7]
NCCN Low Risk Class 26
NCCN Intermediate Risk Class 14
Median F-UP [months] 10 [3-14]
N. of patients with SpaceOAR™ 8
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while limiting toxicity to normal tissues. These innova-
tions provide benefits that are similar to brachytherapy
but with the additional advantage of being non-invasive.
Nevertheless, in the context of definitive local treatment
of prostate cancer, the total duration of a conventional
RT course remains a critical issue for patients because
the standard EBRT course usually lasts from 7 to
9 weeks.
Several studies of RT in prostate cancer suggest that
prostate tumours may have a low alpha/beta ratio (esti-
mated to approximately 1.5-2 in prostate versus 3 in the
rectum) suggesting that the slow proliferating prostate
cancer cells have high sensitivity to dose per fraction.
If low alpha/beta ratio is really low, inferior or equal to
surrounding normal tissue, the linear/quadratic model
suggests that Stereotactic Body Radiation Therapy (SBRT)
delivered in few fractions of focused high doses should
improve the therapeutic ratio in radiotherapy for prostate
cancer. Compared to the use of stereotactic radio-surgeryA
Figure 1 Example of dose distributions in axial, coronal and sagittal v
(B). Colorwash for dose scaling was set in the range 70-110%.for other tumour sites, adoption of SBRT in the manage-
ment of genitourinary malignancies has been slow. Never-
theless, emerging data are showing the safety and efficacy
of this treatment modality in prostate cancer [1].
Stereotactic body radiation therapy (SBRT) with FFF
(Free Flattened Filter) beam is a novel treatment modal-
ity that delivers a very high dose of precise radiation to
the tumour target in a single or small number of frac-
tions. This modality is safe and effective in both early
stage primary cancer and oligo-metastases [2].
Here, we presented a phase II study designed to evalu-
ate the safety of SBRT delivered in 5 fractions on pros-
tate with or without seminal vesicles, by means Rapid
Arc technique with Flattening Filter Free (FFF) beams.
Primary end point of the current analysis was to evaluate
the technical feasibility in terms of dosimetric point of
view and the incidence of acute and early late complica-
tions in the first 40 low-intermediate risk prostate cancer
patients.
Methods
This is a prospective phase I-II pilot feasibility study, ap-
proved in 2012 by internal ethical committee.
Patient population
From February 2012, the recruitment for low-intermediate
risk prostate cancer patients was opened. The main ob-
jective was to study early and late side effects of hypo-
fractionated accelerated RT for prostate cancer with FFF
beam. The schedule chosen was 5×7 Gy = 35 Gy delivered
in 5 alternative days, corresponding to an NTD2 between
70 and 85 Gy for an α/β estimate between 3 and 1.5 Gy.B
iews for one patient without (A) and one patient with SpaceOar
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sibly too intense for the acute mucosal tolerance (the esti-
mated BED for acute mucosal reactions for the schedule
of 7 Gy in 10 elapsed days is 56.7 Gy 10, below 63 Gy 10,
not to be exceeded according to Fowler formula.
Inclusion criteria for patient selection were: Age ≤
80 years; WHO performance status PS ≤ 2; PSA ≤ 20 ng/ml.
Histologically proven prostate adenocarcinoma in which
prophylactic lymph node irradiation is not required, (i.e.
risk of microscopic involvement ≤15% or pN0 after lap-
aroscopic pelvic node dissection in case of a risk >15%);
T1-T2 stage; No pathologic lymph nodes on CT/ MRI
scan; No distant metastases; No previous prostate surgery
other than TURP (at least 6 weeks interval before initi-
ation of RT); No malignant tumours in the previous
5 years; International Prostate Symptom Score (IPSS) in
the range: 0–7; Combined HT according to NCCN risk
factors: short term(4–6 months) neoadjuvant/concomi-
tant/adjuvant androgen deprivation therapy (LHRH ana-
logs and/or antiandrogens) are to propose in all
intermediate risk patients. For intermediate risk, HT
could be avoided in case of significant co-morbidity or
when refused by the patient; Informed consent. Were
considered exclusion criteria: Clinical lymph node metas-
tasis or risk of lymph node involvement >15% [according
to Roach formula for seminal vesicles]; Previous TURP
less than 6 weeks before radiotherapy; Previous prostate
surgery other than TURP; Previous pelvic irradiation; In-
ability to obtain written informed consent. Diabetes, use
of anticoagulants drugs, chronic inflammatory bowel dis-
ease were considered exclusion criteria only for patients
undergoing SpaceOAR™ (Augmenix, Watham, MA-USA)
hydrogel injection.Figure 2 The potential dosimetric role of SpaceOAR™ gel implantatio
CT scan and double planning was performed. Data are shown for CTV,
while remarkable difference was observed in this case for the rectum.Planning and treatment details
For planning and daily treatments patients were re-
quested to present with full bladder and empty rectum.
SpaceOAR™ hydrogel was used in selected cases as
spacer to enlarge the distance between rectal wall and
posterior region of prostate. SpaceOAR™ system is a syn-
thetic hydrogel, implantable and absorbable after several
months after the injection in the body; its usage was
suggested in critical cases, based on physician decision
based on expected potential dosimetric benefit as sug-
gested by Weber et al. and Song et al. [3,4] and it was
injected by trans-perineal injection, with trans-rectal
ultrasound guide. Decision about gel implant was taken
after dosimetric assessment of a treatment plan based on
a CT acquired in absence of it; when plan quality was
expected to be significantly improved, the gel application
was proposed to the patients.
Target definition was based on CT with the support of
MRI for better definition of anatomical relationships be-
tween prostate and rectum and prostate and bladder and
penis bulb and to define urethra position. The clinical
target volume (CTV) was considered the prostate plus
entire seminal vesicles (SV) except for T1-T2 lesions
with a risk of SV involvement of ≤15% in which case
CTV is “prostate only”. In case of higher involvement of
the SV, the first proximal third was included in the tar-
get. Planning target volume (PTV) was defined as CTV +
3-5 mm margin in each direction. During plan optimisa-
tion, the dose-volume constraints for normal tissues had
priority over PTV in case of overlapping regions. Target
coverage was required to be: V95% > 99% on CTV (95% on
PTV). Dose-volume objectives applied for dose optimisa-
tion on organs at risk (OAR) were: for rectum V18Gy < 35%n: dose distribution and DVH for a study patient where double
PTV and rectum. No differences were observed for the target volumes
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ened because technically feasible); V28Gy < 10% (15%);
V32Gy < 5% (10%); D1% < 35 Gy; for bladder D1% < 35 Gy;
for the other organs (femoral heads, penis bulb and
healthy tissue), the strategy was to minimise the involve-
ment as much as possible without compromising the
other objectives).
The plans were designed and optimised according to
the RapidArc technique with 1 or 2 full arcs with the colli-
mator angle set to +/− 30°. Avoidance sectors were
allowed to exclude direct entrance through eventual metal
implants in the femoral heads. All plans were prepared to
be delivered by a TrueBeam linac choosing a 10 MV flat-
tening filter free beam. The dose rate was allowed to range
up to the maximum of 2400 MU/minute.
Treatment delivery was complemented with daily
image guidance by means of cone beam CT (CBCT) ac-
quisition before each fraction delivery. If needed, couch
repositioning was performed after automatic matching
of CBCT images to reference planning CT, followed by
manual adjustments. Fiducial markers were suggested inFigure 3 The average cumulative dose volume histograms (DVH) comthe protocol study for CBCT guidance to reduce set-up
errors. Calcifications can be potential surrogates for
prostate localization and allow for precise image guid-
ance with a low-imaging dose [5]. Thus, we accepted to
use intraprostatic calcifications as markers of prostate
position: intraprostatic calcifications were identified in
all 40 selected patients and exploited as reliable markers
throughout the re-positioning process to drive images
match. Matching was also performed on prostate gland
and other soft tissue structures.
Clinical evaluation, laboratory tests, and follow–up
Physical examination, toxicity assessment and clinical
response with PSA evaluation was performed after 45–
60 days following treatment or if clinically indicated. Sub-
sequently, follow up was performed according to internal
guidelines (every 3 months for the first year and every
6 months after the first year). In patients receiving hormo-
nal treatment, we recommended testosterone levels as a
surrogate for PSA. Toxicity was recorded regularly during
follow-up visits, according to CTAE V.4 classification.puted for the whole cohort of 40 patients (solid lines).
Table 2 Summary of the DVH analysis for the CTV, PTV
and Organs at Risk
Parameter Objective Mean ± SD Range
CTV
Volume = 59.9 ± 21.6 cm3 Range = [25.1 – 110.2] cm3
Mean [Gy] 35 Gy 35.2 ± 0.2 [34.9 - 35.8]
V95% [%] >99% 100.0 ± 0.1 [99.4 - 100.0]
V105% [%] Minimize 0.0 ± 0.0 -
D99% [Gy] >33.2 (95%) 34.5 ± 0.2 [33.9 – 35.1]
D1% [Gy] Minimize 35.9 ± 0.2 [35.5 – 36.8]
PTV
Volume = 107.5 ± 33.7 cm3 Range = [52.8 – 182.2] cm3
Mean [Gy] 35 Gy 35.0 ± 0.1 [34.8 – 35.7]
V95% [%) >95% 98.3 ± 1.1 [95.6 – 99.8]
V105% [%] Minimize 0.0 ± 0.0 -
D99% [Gy] >31.5 (90%) 33.1 ± 0.3 [32.1 – 33.9]
D1% [Gy] Minimize 36.0 ± 0.2 [35.6 – 36.8]
Rectum
Volume = 65.7 ± 20.6 cm3 Range = [33.8 – 113.0] cm3
Mean [Gy] Minimize 12.5 ± 2.5 [6.2 – 16.1]
D1% [Gy] <35 Gy 33.0 ± 2.4 [22.4 – 34.9]
D1cm3 [Gy] <35 Gy 32.3 ± 2.9 [20.1 – 34.9]
V18Gy [%] <35% (50%) 27.9 ± 9.6 [3.9 – 42.5]
V28Gy [%] <10% (15%) 7.5 ± 3.5 [0.1 – 14.9]
V32Gy [%] <5% (10%) 3.1 ± 1.9 [0.0 – 7.1]
Bladder
Volume = 195.8 ± 118.1 cm3 Range = [61.5 – 544.9] cm3
Mean [Gy] Minimize 9.1 ± 4.4 [3.1 – 19.4]
D1% [Gy] <35 Gy 34.1 ± 1.8 [27.5 – 35.6]
Right femoral head
Volume = 73.7 ± 39.9 cm3 Range = [37.2 – 186.0] cm3
D1% [Gy] Minimize 10.3 ± 2.1 [4.4 – 13.8]
Left femoral head
Volume = 71.8 ± 37.6 cm3 Range = [33.7 – 183.2] cm3
D1% [Gy] Minimize 11.3 ± 1.7 [6.4 – 14.3]
Penile bulb
Volume = 4.2 ± 1.9 cm3 Range = [1.1 – 9.0] cm3
Mean [Gy] Minimize 8.9 ± 5.6 [1.2 – 21.8]
D1% [Gy] Minimize 20.7 ± 11.2 [2.3 – 35.4]
Dx%: dose received by at least x% of the volume; Vx%: volume receiving at
least x% of the dose.
Data are reported as average values plus or minus standard deviation
and range.
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Descriptive data of the cohort of the 40 recruited pa-
tients of the trial were summarized in Table 1.
Dosimetric data
Figure 1 presents an example of dose distributions in
axial, coronal and sagittal views for one patient without
(A) and one patient with SpaceOar (B). Color wash for
dose scaling was set in the range 70-110%. When
SpaceOAR™ gel implantation was performed, its poten-
tial dosimetric role was evaluated as shown for a study
patient in Figure 2.
Figure 3 shows the average cumulative dose volume
histograms (DVH) computed for the whole cohort of 40
patients (solid lines). The dashed lines represent the
inter-patient variability expressed at + −1 standard devi-
ation. Table 2 summarised the numerical analysis
performed on CTV, PTV and OARs and based on
DVHs. Reported are the main parameters valuable for
plan assessment, the corresponding planning objectives,
the mean values of the findings (with 1 standard devi-
ation uncertainty) and the observed range. As it can be
derived from the table, all objectives were met by all
patients.
Clinical data: toxicity assessment
With a median follow-up of 11 months (5–16), 40 pa-
tients were recruited in the protocol and treated with
the accelerated schedule of 35 Gy in 5 fractions, and
were evaluable for the current analysis.
According to NCCN criteria, 26/40 patients were strati-
fied as low-risk and 14/40 were stratified as intermediate
risk. Median Age was 70 (56–80), median initial PSA was
6.25 ng/ml (0.50-13.43 ng/ml). Median Gleason score was
6 (6–7). Median treatment duration was 11.8 days (9–22).
HT was prescribed in 10/40 (25%) patients, all included in
NCCN intermediate risk class. All patients completed the
SBRT as programmed. Median treatment time was
126 seconds (120–136).
Acute Toxicities were recorded as follow: rectum G0
in 30/40 cases (75%), G1 in 6/40 (15%); G2 in 4/40
(10%). Genito-urinary (GU) G0 in 16/40 cases (40%),
G1 in 8/40 (20%), G2 in 16/34 (40%). In two G2 urin-
ary retention cases, the placement of intermittent cath-
eter was needed (in both cases prostate dimension was
superior to 100 cm3). No acute G3-5 was found in the
trial and 'out of trial' patients. Late toxicity (more than
6 months of follow-up) was evaluable in 25/40 trial pa-
tients. No late rectum toxicity was found; three cases of
late GU G1 were found and only a case of G2 GU was
experienced.
SpaceOAR™ was implanted in 8 patients with a single
case of rectal fascia infection resolved with antibiotics.
During Follow-up, PSA reduction was documented in alltreated patients. Figure 2 shows the difference in dose
distributions and DVH shape for a study patient treated
with the gel and planned twice (with and without it). No
differences were observed for the target volumes while
remarkable difference was observed in this case for the
rectum.
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SBRT is a promising technique that offers the ability to
treat various types of solid tumours with efficacy and
minimal side effects. In early non-small cell lung cancer,
SBRT has yielded results comparable to those obtained
with surgery, with rates of local control up to 90% in
several series. Although experience to date with SBRT in
prostate cancer is promising, this treatment is still in its
infancy as a therapeutic option for this disease due to
the small number of patients who have been treated and
the relatively short follow-up [1].
In recent years, several clinical studies have employed
only a few very large dose fractions, mainly in low risk,
localized prostate cancer, with the aim of exploring the
feasibility of such extreme hypo-fractionation schedules.
A strong interest amongst the radiation oncologist com-
munity in the adoption of SBRT for localized prostate
cancer has also recently prompted the Radiation Ther-
apy Oncology Group (RTOG) to open a randomized
non-inferiority Phase II trial, RTOG 0938, comparing
delivery of 36.25 Gy in 5 fractions over 2 weeks to 51.6
Gy in 12 fractions over 2.5 weeks [5]. The attempt to
further reduce the treatment duration in prostate cancer
is based on the emulation of the HDR- brachytherapy
hypo-fractionated approach in an alternative, more suit-
able way, allowing for steep dose gradients that resemble
brachytherapy dose distributions, without the need for
hospitalization, catheterization and the discomfort of
keeping the delivery needles inserted for an extended
time period.
Several prospective trials of extreme hypo-fractionation
have already been published and several others are cur-
rently underway. The results of the more relevant SBRT
trials are summarized in Table 3 [7-15]. Many of these tri-
als were carried out by the Cyberknife® and were plannedTable 3 Summary of outcomes from SBRT trials with a follow
patients







Katz et al. 2010 [5] 35 – 36.25 Gy in 5 fx 304 L-I-H 48
Freeman, King, 2011. [6] 7-7.25 Gy in 5 fx 41 L 60
McBride et al. 2012 [7] 36.25-37.5 Gy in 5 fx 45 L 44
Fuller et al. [8] 38 Gy in 4 fx † 54 L-I 36
Kang et al. [9] 32-36 Gy in 4 fx 44 L-I-H 40
King et al. 2012 [10] 36.25 Gy in 5 fx 67 L 32
Gantry-based Systems
Madsen et al. 2007 [11] 33.5 Gy in 5 fx 40 L 41
Boike et al. 2011 [12] 45-50 Gy in 5 fx 45 L-I 30
Abbreviations: L = low; I = intermediate; H = high.to explore the feasibility of applying the shorter schedules
to treat low/intermediate risk, localized prostate cancer.
The premature results of these studies, although asso-
ciated with good treatment tolerance, excellent early bio-
chemical outcomes and low, late toxicity rates, did not
lead to any firm conclusions on the clinical benefits of
these regimens in comparison to escalated conventional
dose fractionation. Noteworthy, among all hypo-
fractionated regimes, very few experiences reported on
acute toxicity either in the SBRT or in the moderately
fractionated approach: among seven randomized trials
[15-21], a detailed description of acute toxicity was
reported only in two trials [21,22]. Differently from late
toxicity, acute rectal toxicity occurs during or within
3 months after completion of treatment and is tempor-
ary. However, the acute effects may be severe enough to
interrupt the planned course of treatment in 10% of the
patients. In addition, with conventional fractionation re-
gimes, a high rate of acute rectal toxicity is now recog-
nized to be associated with late proctopathy [23]. Both
studies reported a slightly higher but not statistically sig-
nificant rate of grade 2 or more GI and GU acute tox-
icity in the short over the long treatment arms, with an
earlier peak for both rectal and urinary toxicity in the
former arm. Arcangeli et al. [22], found that the me-
dian interval to toxicity detection was 22 and 36 days
(p = 0.001) for GI and 15 and 23 days (p = 0.002) for
GU in the hypo-fractionation and conventional frac-
tionation arm, respectively, but no difference in the
duration of either GI or GU toxicities was encoun-
tered between the two treatment schedules (p = 0.31
and 0.34, respectively).
In the present study, a result to underline is the ab-
sence of G3 or greater toxicity in GU and rectum. The








2% - 97, 93, 75% at 4 year
< 1% - 93% at 5 year
.5 < 1% - 97.7% at 3 years
4% - 96% at 3 years
- - 100%, 100%, 90.9%
at 5 years
.4 3.5% - 94% at 4 years
- - 90% at 4 years
, 18, 12 4% 2% plus 1 Grade 4 100% at 1–2.5 years
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SBRT has been tested for prostate cancer patients.
The main limit of the present report remains the short
follow-up (approximately 11 months), un-sufficient to
determine late toxicity and FFBF rates. Nevertheless,
toxicity reported with 8 months or greater of follow-up,
evaluable in 25 of 40 patients, seems to confirm the op-
timal preliminary tolerability of the treatment approach:
only three cases of late GU G1, a case of G2, and no
cases of late rectum toxicity has been reported. Given
the absence of relapses in the treated patients, also pre-
liminary data on biochemical control seems to be prom-
ising and in line with those published in other series, as
shown in Table 3.
The current 3 to 4-year FFBF rates of >90%, reported
in all SBRT published trials with a sufficient follow-up
[7-15], seems to be consistent with the 5-year rates of
~90%–95% reported in trials of conventional escalated
doses of 78-80 Gy. However, given the uncertainties,
which exist in extrapolating biological effects to very
large fraction size, these results need to be confirmed by
appropriate randomized trials with a sufficiently long
follow-up and accurate evaluation of long term tolerance
and toxicity, particularly of the urethra which is an un-
avoidable organ at risk in the irradiation of prostate
cancer.
Another possible criticism of the present study regards
the use of SpaceOAR™. The hydrogel spacer was im-
planted, based on physician decision, only in a limited
subgroup of trial patients, considered critical. We are
conscious on the subjectivity of this choice. However, in
the absence of general consensus, the institutional ex-
perience suggests that the use of the spacer might be
beneficial from the dosimetric viewpoint, in a subgroup
of patients to be accurately selected.
In summary, our early findings suggest that LINAC
based SBRT FFF treatment for prostate cancer in 5 frac-
tions is feasible, fast and well tolerated in acute setting.
Longer follow-up is needed for definitive assessment of
late toxicity and clinical outcome.
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